Burimamide

Burimamide

Burimamide is a histamine antagonist and the first H2 receptor antagonist to be discovered. It was developed by Sir James Black and his team at Smith, Kline & French in the 1970s. Burimamide is a specific antagonist of the histamine H2 receptor, which is found in the stomach lining and is responsible for stimulating gastric acid secretion.

History

Burimamide was the first H2 receptor antagonist to be discovered. It was developed by Sir James Black and his team at Smith, Kline & French in the 1970s. The discovery of burimamide led to the development of cimetidine, the first H2 receptor antagonist to be marketed.

Pharmacology

Burimamide is a specific antagonist of the histamine H2 receptor. This receptor is found in the stomach lining and is responsible for stimulating gastric acid secretion. By blocking this receptor, burimamide reduces the production of stomach acid.

Clinical use

While burimamide itself is not used clinically, its discovery led to the development of cimetidine, which is used to treat conditions such as peptic ulcers and gastroesophageal reflux disease (GERD).

See also

• Histamine H2 receptor
• Cimetidine
• Peptic ulcer
• Gastroesophageal reflux disease

This article is a stub related to pharmacology. You can help WikiMD by expanding it!